AP2218A - Azithromycin dosage forms with reduced side effects - Google Patents

Azithromycin dosage forms with reduced side effects

Info

Publication number
AP2218A
AP2218A APAP/P/2004/003145A AP2004003145A AP2218A AP 2218 A AP2218 A AP 2218A AP 2004003145 A AP2004003145 A AP 2004003145A AP 2218 A AP2218 A AP 2218A
Authority
AP
ARIPO
Prior art keywords
azithromycin
alkalizing agent
effective amount
dosage form
glyceryl
Prior art date
Application number
APAP/P/2004/003145A
Other versions
AP2004003145A0 (en
Inventor
Timothy Arthur Hagen
Scott Max Herbig
Julian Belknap Lo
Avinash Govind Thombre
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas Friesen
David Keith Lyon
Scott Baldwin Mccray
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority claimed from PCT/IB2004/001654 external-priority patent/WO2005053650A1/en
Publication of AP2004003145A0 publication Critical patent/AP2004003145A0/en
Application granted granted Critical
Publication of AP2218A publication Critical patent/AP2218A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.
APAP/P/2004/003145A 2003-12-04 2004-05-14 Azithromycin dosage forms with reduced side effects AP2218A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
PCT/IB2004/001654 WO2005053650A1 (en) 2003-12-04 2004-05-14 Azithromycin dosage forms with reduced side effects

Publications (2)

Publication Number Publication Date
AP2004003145A0 AP2004003145A0 (en) 2004-09-30
AP2218A true AP2218A (en) 2011-04-20

Family

ID=34699855

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003145A AP2218A (en) 2003-12-04 2004-05-14 Azithromycin dosage forms with reduced side effects

Country Status (8)

Country Link
CN (1) CN1697648B (en)
AP (1) AP2218A (en)
AU (1) AU2004216676B2 (en)
EC (1) ECSP045351A (en)
GT (1) GT200400183A (en)
TN (1) TNSN05319A1 (en)
UA (1) UA78793C2 (en)
ZA (1) ZA200408075B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200805793B (en) * 2005-12-22 2009-11-25 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
CN103054813A (en) * 2012-12-31 2013-04-24 广东先强药业有限公司 Azithromycin oral sustained-release dry suspension and preparation method thereof
CN104177457A (en) * 2013-05-23 2014-12-03 长春海悦药业有限公司 Azithromycin drug raw material, and preparation and application thereof
CN107427494A (en) * 2015-03-10 2017-12-01 卢莫斯制药公司 The micro- supensoid agent of circular muscle acid
CA3051914A1 (en) * 2017-02-02 2018-08-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
CN114213484A (en) * 2021-12-21 2022-03-22 河北远征药业有限公司 Tildipirosin 1, 2-propylene glycol solvent compound and preparation method thereof
CN115212173A (en) * 2022-07-11 2022-10-21 上海现代药物制剂工程研究中心有限公司 Ambroxol hydrochloride spherical sustained-release particles, preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679400A1 (en) * 1994-04-29 1995-11-02 Pfizer Inc. Oral dosage forms of azithromycin avoiding drugfood interaction
US5633006A (en) * 1992-07-30 1997-05-27 Pfizer Inc. Taste-masking composition of bitter pharmaceutical agents
WO2003063838A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1123279A (en) * 1995-06-15 1996-05-29 沈家祥 Azithmycin water-soluble salt, injection thereof and their usage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633006A (en) * 1992-07-30 1997-05-27 Pfizer Inc. Taste-masking composition of bitter pharmaceutical agents
EP0679400A1 (en) * 1994-04-29 1995-11-02 Pfizer Inc. Oral dosage forms of azithromycin avoiding drugfood interaction
WO2003063838A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin

Also Published As

Publication number Publication date
CN1697648B (en) 2010-06-23
AU2004216676A1 (en) 2005-06-23
AU2004216676B2 (en) 2011-06-16
ZA200408075B (en) 2007-01-31
AP2004003145A0 (en) 2004-09-30
ECSP045351A (en) 2005-01-28
TNSN05319A1 (en) 2007-07-10
UA78793C2 (en) 2007-04-25
CN1697648A (en) 2005-11-16
GT200400183A (en) 2005-10-24

Similar Documents

Publication Publication Date Title
TW200518784A (en) Azithromycin dosage forms with reduced side effects
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
WO2012079092A3 (en) Testosterone undecanoate compositions
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
WO2011160136A3 (en) Progesterone containing oral dosage forms and related methods
FR11C0017I1 (en)
EP1708685A4 (en) Effervescent oral opiate dosage forms and methods of administering opiates
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
RU2011152105A (en) COMPOSITIONS OF 3-CYANOCHINOLINE TABLETS AND THEIR APPLICATION
NZ532063A (en) Methods for wet granulating azithromycin
AP2003002763A0 (en) Controlled release formulations for oral administration
MX2007010886A (en) Acarbose methods and formulations for treating chronic constipation.
AP2218A (en) Azithromycin dosage forms with reduced side effects
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
PL1648473T3 (en) Single dose fast dissolving azithromycin
WO2003105811A3 (en) Controlled release compositions and methods for using same
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
NZ595798A (en) Ectoparasiticidal methods and formulations
MD3121F1 (en) Method of viral hepatitis B prophylaxis
RU2002126216A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF LIVER FIBROSIS AND CIRROSIS
EP1347754A4 (en) Compositions for adhesion prevention
TW200611686A (en) Effervescent oral opiate dosage forms and methods of administering opiates
WO2006036956A3 (en) Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents
GB0224492D0 (en) Pharmaceutical compositions of rapid drug delivery system to carry active ingredients for fast dissolving tablets by mouth administration